Search Results

Filter
  • 1-10 of  41,467 results for ""OMALIZUMAB""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Solar Urticaria and Omalizumab: A Retrospective Case-Control Study and Follow-Up.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/adverse effects ; Urticaria*/Urticaria*/Urticaria*/drug therapy

  • Source: Actas dermo-sifiliograficas [Actas Dermosifiliogr] 2024 Oct; Vol. 115 (9), pp. T931-T932. Date of Electronic Publication: 2024 Jun 24.Publisher: Elsevier España Country of Publication: Spain NLM ID: 0373062 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Cost-effective omalizumab dosage for chronic urticaria: a systematic review and network meta-analysis.

  • Authors : Tajerian A; School of Medicine, Arak University of Medical Sciences, Arak, Iran.; Pourvali A

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/economics ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use

  • Source: Archives of dermatological research [Arch Dermatol Res] 2024 Dec 14; Vol. 317 (1), pp. 131. Date of Electronic Publication: 2024 Dec 14.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X

Record details

×
Academic Journal

Chest CT assess the impact of omalizumab treatment on airway remodeling in refractory asthma.

  • Authors : Shi H; Department of Respiratory and Critical Care Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/pharmacology ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2024 Dec; Vol. 87, pp. 102329. Date of Electronic Publication: 2024 Oct 03.Publisher: Academic Press Country of Publication: England NLM ID: 9715279 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Long-term use of omalizumab in patients with allergic bronchopulmonary aspergillosis: a tertiary-level care center experience.

  • Authors : Cakmak ME; Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.; Öztop N

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Aspergillosis, Allergic Bronchopulmonary*/Aspergillosis, Allergic Bronchopulmonary*/Aspergillosis, Allergic Bronchopulmonary*/drug therapy

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Dec; Vol. 61 (12), pp. 1663-1671. Date of Electronic Publication: 2024 Jul 08.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab.

  • Authors : Auyeung KL; Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Kim BS

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Pruritus*/Pruritus*/Pruritus*/drug therapy

  • Source: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2371545. Date of Electronic Publication: 2024 Jul 07.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.

  • Authors : Zhu R; Genentech, Inc., South San Francisco, California, USA.; Schoemaker R

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Omalizumab*/Omalizumab*/Omalizumab*/pharmacokinetics ; Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use

  • Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Dec; Vol. 90 (12), pp. 3190-3200. Date of Electronic Publication: 2024 Aug 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Efficacy and safety of subcutaneous immunotherapy combined with omalizumab in children with dust mite-induced asthma.

  • Authors : Long C; Department of Pediatrics (III), Linyi People's Hospital, Linyi, Shandong, China.; Sun C

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Omalizumab*/Omalizumab*/Omalizumab*/adverse effects

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Nov; Vol. 61 (11), pp. 1561-1570. Date of Electronic Publication: 2024 Jul 01.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab.

  • Authors : Cilli A; Department of Respiratory Disease, Akdeniz University, Antalya, Türkiye.; Uzer F

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Asthma*/Asthma*/Asthma*/drug therapy

  • Source: The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Nov; Vol. 61 (11), pp. 1469-1476. Date of Electronic Publication: 2024 Jun 08.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria.

  • Authors : Ji P; Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.; Chen H

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Cytokines*/Cytokines*/Cytokines*/blood ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy

  • Source: Cytokine [Cytokine] 2025 Jan; Vol. 185, pp. 156814. Date of Electronic Publication: 2024 Nov 27.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005353 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Eosinophilic cationic protein and D-Dimer are potential biomarkers to predict response to antihistamines but not to omalizumab in chronic spontaneous urticaria.

  • Authors : Atik Ö; Allergy and Immunology Clinic, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.; Tepetam FM

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/blood

  • Source: The Libyan journal of medicine [Libyan J Med] 2024 Dec 31; Vol. 19 (1), pp. 2420483. Date of Electronic Publication: 2024 Oct 28.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101299403 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
  • 1-10 of  41,467 results for ""OMALIZUMAB""